BRAF and cancer: To determine whether eCas12f1 effectively targets cancer-specific mutations and could be evaluated as a potential tool for cancer therapy, we designed an sgRNA targeting the BRAF V600E mutation in the A375 cell line (Fig. 5e and Supplementary Fig. 9a).